申请人:Merck & Co., Inc.
公开号:US06645939B1
公开(公告)日:2003-11-11
&bgr;-Alanine derivatives of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
公式I中的β-丙氨酸衍生物是VLA-4和/或α4β7的拮抗剂,因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中非常有用。这些化合物可以制成药物组合物,并适用于治疗哮喘、过敏、炎症、多发性硬化症和其他炎症性和自身免疫性疾病。